Beyond Air — Q3 2026 Earnings Summary

Beyond Air reported a record quarterly revenue of $2.3 million for the period ended September 30, 2026, marking a 28% year-over-year increase. The company reaffirmed its full-year 2026 revenue guidance of $8 million and its 2027 guidance of $16 million to $18 million, contingent on FDA approval for its second-generation LungFit PH system. During the quarter, the company incurred a net loss of $7.8 million, or $3.76 per share, while maintaining $18.5 million in cash and equivalents. Additionally, Beyond Air announced the sale of its controlling interest in NeuroNOS Israel Ltd. and received FDA Breakthrough Device Designation for its LungFit GO product.